SynchroMed™ III Implantable infusion system
SynchroMed™ III is an implantable targeted drug infusion system that helps manage chronic pain, cancer pain, and severe spasticity.
Contact us
Overview
Simple, safe and effective intrathecal therapy made possible
Unlike medications that must be absorbed systemically and must cross the blood-brain barrier, an implanted SynchroMed™ III programmable pump and catheter deliver prescribed amounts of medication directly into the intrathecal space.
Targeted drug delivery (TDD) into the intrathecal space offers effective relief at a fraction of the systemic dose, which can reduce side effects.1-3
The SynchroMed™ III implantable infusion system provides:
- State-of-the-art pump electronics to enable enhanced long-term reliability and wireless firmware upgradability to facilitate expanded capabilities
- End-to-end cybersecurity controls for enhanced patient data protection
- Refill-only workflow, which enables a shorter and more consistent update duration during this common clinician device interaction
- Continued peace of mind with proven durable design enhancements built into the SynchroMed™ II pump, which have increased pump survival rate to 99%.*
Product details
SynchroMed™ III is an upgraded system compared to the SynchroMed™ II system, featuring a new “refill only” physician workflow for more efficient programming, improved electronics capable of delivering firmware upgrades to implanted devices, and additional protections for patient data through enhanced cybersecurity.
Allows full-body 1.5 and 3T MRI† scans under specific conditions
Updated electronics
New chipset and firmware allow end-to-end cybersecurity controls and an upgradable platform.
Updated programming
Refill-only workflow enables a shorter and more consistent update duration.
Proven performance
Reliability by design with proven durable design enhancements from SynchroMed™ II infusion pump
2011
Battery coating
added
2015
Gearwheel 3 material change added
2015
Feedthroughs encapsulated
added
2017
Diamond-like carbon (DLC) coating added
Enhanced for reliability
Let the data do the talking
Pump survival rate over time*
Simple, safe & effective, offering valuable time with their loved ones, for patients with refractory cancer pain.
Simple
Easier Programming for clinicians with the refill-only workflow.28
Automatic drug delivery reduces therapy burden and offers personalised treatment fitting patients’ lifestyle.5, 29
Safe
More patients with
reduced side effects.1,2,5,6
Effective
More patients with
increased pain control.1,2,5,6
Simple, safe & effective, improving care and function in patients with severe spasticity
Simple
Easier Programming for clinicians with the refill-only workflow.28
Automatic drug delivery reduces caregiver burden and offers personalised treatment fitting patients’ lifestyle.9, 10, 29
Safe
Fewer or more tolerable side effects are expected compared to oral medication.11
Effective
ITB Therapy can help improve function, activities of daily living, and ease of care.12-14
Patient satisfaction
Chronic pain
90%
of patients would recommend the therapy to a family member or friend.4
Cancer pain
94%
reduction in systemic opioid.7
Spasticity
99%
of severe spasticity patients
choose to replace the pump at the
end of battery life.8
Ordering information
| Item | Description |
| SynchroMed™ III pump (8667-20 and 8667-40) | SynchroMed™ III pump with 20 mL and 40 mL reservoir capacities both redesigned with new electronics and firmware (upgradability and cybersecurity). |
| SynchroMed™ Clinician Programmer CT900 tablet with A810 software v2.x | Clinician programmer with the new refill-only workflow that streamlines clinician programming. |
| TH90T02 patient programmer with A810 software v2.x | myPTM™ Personal Therapy Manager with added information intended to better support patient understanding of clinician restrictions for patient bolus activation. |
*
This data represents pumps with four durable design changes (battery coating, gear wheel 3 material change, feedthrough encapsulation, diamond-like carbon coating). The most recent design change was implemented in 2017. At four years, the survival probability (95% confidence intervals) was 97% pump survival rate pre-enhancements (n=3158 pumps) and 99.4% post-durable enhancements (n=203 pumps). Source: 2022 Product Performance Report.
†
Under specific conditions. Refer to product labeling for full list of conditions: https://manuals.medtronic.com/manuals/mri/region
1
Hamza, M et al. Pain Medicine. (United States) 13, 1304–1313 (2012). doi: 10.1111/j.1526-4637.2012.01451.x
2
Smith, TJ et al. Journal of Clinical Oncology. 20, 4040–4049 (2002). doi: 10.1200/JCO.2002.02.118
3
Rushton, DN. Upper Motor Neurone Syndrome and Spasticity: Chapter 10. ed. Barnes, MP and Johnson, GR pages 181–192. (Cambridge University Press, 2008). doi:10.1017/cbo9780511544866.011.
4
Deer, T et al. Pain Medicine. doi: 10.1111/j.1526-4637.2004.04011.x
5
Smith TJ, Coyne PJ. J Palliat Med. 2005;8(4):736–742. doi: 10.1089/jpm.2005.8.736
6
Grider JS, Etscheidt MA, Harned ME, et al. Neuromodulation. 2016;19(2):206-219. doi:10.1111/ner.12352.
7
Sindt et al. Neuromodulation. 2020; 23(7):978-983. doi: 10.1111/ner.13175
8
Schiess MC, Eldabe S, Konrad P, et al. Neuromodulation. 2020;23(7):996-1002. doi:10.1111/ner.13097.
9
Meythaler JM, McCary A, Hadley MN. J Neurosurg. 1997;87(3):415-419. doi: 10.3171/jns.1997.87.3.0415
10
Ordia JI, Fischer E, Adamski E, Chagnon KG, Spatz EL. Neuromod. 2002;5(1):16-24. doi: 10.1046/j.1525-1403.2002._2004.x
11
Ertzgaard P, Campo C, Calabrese A. J Rehabil Med. 2017 Mar 6;49(3):193-203. doi: 10.2340/16501977-2211
12
Ivanhoe CB, Francisco GE, McGuire JR, Subramanian T, Grissom SP. Arch Phys Med Rehabil. 2006;87(11):1509–1515. doi: 10.1016/j.apmr.2006.08.323
13
Dario A, Scamoni C, Bono G, et al. Funct Neurol. 2001;16:311-315. PMID: 11853321
14
Krach LE, Nettleton A, Klempka B. Pediatr Rehabil. 2006;9(3):210-218. doi: 10.1080/13638490500138678
15
Borrini L, Bensmail D, Thiebaut JB, Hugeron C, Rech C, Jourdan C. Arch Phys Med Rehabil. 2014;95(6):1032-1038. doi:10.1016/j.apmr.2013.12.019.
16
Copley S, Yassa PE, Batterham AM, et al. Neuromodulation. 2023;26(6):1240-1246. doi:10.1016/j. neurom.2022.10.05.
17
Brogan SE, Winter NB, Okifuji A. Reg Anesth Pain Med. 2015;40(4):369–75. doi: 10.1097/AAP.0000000000000251
18
Vles GF, Soudant DL, Hoving MA et al. Eur J Paediatr Neurol. 2013;17(6):639-644. doi: 10.1016/j.ejpn.2013.06.003
19
Hoving MA, van Raak EP, Spincemaille GH, Palmans LJ, Becher JG, Vles JS. Eur J Paediatr Neurol. May 2009;13(3):240-246. doi: 10.1016/j.ejpn.2008.04.013
20
Francisco GE, Boake C. Arch Phys Med Rehabil. 2003;84(8):1194-1199. doi: 10.1016/s0003-9993(03)00134-5
21
Nanninga JB, Frost F, Penn R. J Urol. 1989;142:101- 105. doi: 10.1016/s0022-5347(17)38673-1
22
Sadiq SA, Wang GC. J Neurol. 2006;253(5):563-569. doi: 10.1007/s00415-005-0060-4
23
Bhatia G, Lau ME, Koury KM, Gulur P. F1000Res. 2013;2:96. doi:10.12688/f1000research.2-96.v4.
24
Melthaler JM, McCary A, Hadley MN. J Neurosurg. 1997;87(3):415-419. doi: 10.3171/jns.1997.87.3.0415
25
Creamer M, Cloud G, Kossmehl P, et al. J Neurol Neurosurg Psychiatry. 2018 Jun;89(6):642-650. doi: 10.1136/jnnp-2017-17021.
26
Penn RD, Savoy SM, Corcos D, et al. N Engl J Med. 1989; 320: 1517-1521. doi: 10.1056/NEJM198906083202303
27
Breivik H, Cherny N, Collett B, et al. Ann. Oncol. 20 1420–33. doi: 10.1093/annonc/mdp001
28
NDHF1593-220433, SynchroMed X Clinician Programming Marketing Claims Characterization Test Report [SMII: 44.1sec, SMIII: 5.6sec (statistically significant: tighter standard deviation for SMIII]
29
SynchroMed™ A810 Clinician Programmer Application Clinician Programming Guide M968017A035 Rev A. Published online August 15, 2022. Accessed July 4, 2024. https://manuals.medtronic.com/